BMO Capital Markets Analysts Give Eli Lilly and Company (LLY) a $73.00 Price Target

BMO Capital Markets set a $73.00 target price on Eli Lilly and Company (NYSE:LLY) in a report issued on Tuesday, October 24th. The brokerage currently has a sell rating on the stock.

Several other equities research analysts have also commented on the company. Leerink Swann boosted their price target on Eli Lilly and from $92.00 to $93.00 and gave the stock a market perform rating in a research note on Monday, October 23rd. Piper Jaffray Companies reissued a buy rating and set a $105.00 price target on shares of Eli Lilly and in a research note on Friday, October 13th. Barclays PLC boosted their price target on Eli Lilly and from $90.00 to $98.00 and gave the stock an overweight rating in a research note on Friday, October 13th. Credit Suisse Group downgraded Eli Lilly and from an outperform rating to a neutral rating and lifted their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a hold rating in a research report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of $89.76.

Eli Lilly and (NYSE LLY) opened at $83.29 on Tuesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and has a twelve month low of $64.18 and a twelve month high of $89.09. The stock has a market capitalization of $91,710.20, a PE ratio of 20.36, a P/E/G ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. analysts expect that Eli Lilly and will post 4.22 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/bmo-capital-markets-analysts-give-eli-lilly-and-company-lly-a-73-00-price-target-2.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 770,000 shares of company stock valued at $64,669,850 over the last 90 days. 0.20% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Airain ltd acquired a new position in Eli Lilly and in the 2nd quarter worth approximately $567,000. Buckingham Asset Management LLC lifted its position in Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after buying an additional 568 shares in the last quarter. Joel Isaacson & Co. LLC lifted its position in Eli Lilly and by 1.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares in the last quarter. BSW Wealth Partners lifted its position in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after buying an additional 27 shares in the last quarter. Finally, Sumitomo Life Insurance Co. lifted its position in Eli Lilly and by 4.4% in the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after buying an additional 1,370 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply